Kashiv BioSciences announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing Xolair, with Amneal Pharmaceuticals for the United States. Omalizumab, which targets free IgE, is a humanized monoclonal antibody. It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria, and is typically administered in a hospital or clinic setting. The biosimilar was developed by Kashiv BioSciences, and is currently in a Phase III clinical trial, which began in the third quarter of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals management to meet virtually with Piper Sandler
- Amneal starts supplying OTC Naloxone HCI Nasal Spray to U.S. retail, California
- Amneal Pharmaceuticals price target raised to $9 from $7 at Truist
- Amneal Pharmaceuticals backs FY24 adjusted EPS view 53c-63c, consensus 58c
- Amneal Pharmaceuticals reports Q1 adjusted EPS 14c, consensus 9c